Labopharm To Host Conference Call Thursday, October 28, 2004 At 8:30 A.M. (ET)

- Management to discuss third quarter fiscal 2004 results -

Oct 19, 2004, 01:00 ET from Labopharm Inc.

    LAVAL, QC, Oct. 19 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS)
 today announced that it will host a conference call on Thursday, October 28,
 2004 at 8:30 a.m. (ET) to discuss its third quarter fiscal 2004 results.
 Labopharm will report its third quarter fiscal 2004 results via news release
 at approximately 7:00 a.m. the same day.
     To access the conference call by telephone, dial 416-405-9328 or
 1-800-387-6216. Please connect approximately fifteen minutes prior to the
 beginning of the call to ensure participation. The conference call will be
 archived for replay until Thursday, November 4, 2004 at midnight. To access
 the archived conference call, dial 416-695-5800 or 1-800-408-3053 and enter
 the reservation number 3106764 followed by the number sign.
     A live audio webcast of the conference call will be available at and Please connect at least
 15 minutes prior to the conference call to ensure adequate time for any
 software download that may be required to join the webcast. The webcast will
 be archived at the above web sites for 90 days.
     About Labopharm Inc.
     Labopharm Inc. (TSX:DDS) is an international specialty pharmaceutical
 company focused on the development of drugs incorporating the Company's
 proprietary advanced controlled-release technology, Contramid(R). Contramid(R)
 can be applied to a wide variety of drugs in solid oral dosage form, improving
 their oral administration and performance, and is used to develop products
 that are either bio-equivalent to existing, branded products, or are new
 branded products. The Company's pipeline includes a combination of both
 in-house and partnered programs with products both in clinical trials and in
 preclinical development. Labopharm is also developing novel polymeric
 nano-delivery systems for delivery of water-insoluble and poorly bio-available
 drugs. For more information, please visit
     This press release contains forward-looking statements, which reflect the
 Corporation's current expectations regarding future events. The
 forward-looking statements involve risks and uncertainties. Actual events
 could differ materially from those projected herein and depend on a number of
 factors, including the successful and timely completion of clinical studies,
 the uncertainties related to the regulatory process and the commercialization
 of the drug thereafter. Investors should consult the Corporation's ongoing
 quarterly filings and annual reports for additional information on risks and
 uncertainties relating to these forward-looking statements. The reader is
 cautioned not to rely on these forward-looking statements. The Corporation
 disclaims any obligation to update these forward-looking statements.

SOURCE Labopharm Inc.